Naline E, Bardou M, Devillier P, Molimard M, Dumas M, Chalon P, Manara L, Advenier C
Département de Pharmacologie, Faculté de Médecine Paris-Ouest, 15 Rue de Lécole de Médecine, Paris, France.
Pulm Pharmacol Ther. 2000;13(4):167-74. doi: 10.1006/pupt.2000.0246.
In the human isolated bronchus (HIB) it has been shown that beta(3)-adrenoceptor stimulation fails to induce relaxation of airway smooth muscle. It has however been reported in human ventricular endomyocardial biopsies that beta(3)-adrenoceptor stimulation induced a marked negative inotropic effect which could be linked to Gi protein activation. The aims of this study were: (1) to determine in HIB (internal diameter 1-2 mm) whether the selective beta(3)-adrenoceptor agonist SR 59119A (N[7-methoxy-1,2,3, 4-tetrahydronaphthalen-(2R)methyl]-(2R)-2-hydroxy-2-(3-chloroph eny l)e thanamine hydrochloride) was able to inhibit adenylate-cyclase-mediated airway smooth muscle relaxation induced by isoprenaline, forskolin or vasoactive intestinal peptide (VIP) and (2) to investigate the role of the Gi protein in this interaction. SR 59119A (0.1 microM and 1 microM) induced a shift to the right of concentration response curve for isoprenaline (-0. 15+/-0.06 and -0.54+/-0.21 log unit, P<0.05 and P<0.01 respectively), forskolin (-0.12+/-0.02 and -0.30+/-0.05 log unit, P<0.001), and VIP (-0.42+/-0.12 log unit, P<0.01 with SR59119A 10(-6)M). The inhibitory effect of SR 59119A was (1) abolished by an incubation of HIB with pertussis toxin (1 microg/ml, during 15 h in Krebs-Henseleit solution, at 21 degrees C), which is known to inactivate the Gi protein and (2) increased after an incubation of HIB with the pro-inflammatory cytokine IL-1beta (10 ng/ml, during 15 h in Krebs-Henseleit solution, at 21 degrees C), which is known to up-regulate Gi protein expression. Our results suggest that the selective beta(3)-adrenoceptor agonist SR59119A might inhibit the cAMP-dependent relaxation of human isolated bronchus through Gi protein-mediated inhibition of adenylate cyclase.
在人离体支气管(HIB)中,已有研究表明β3-肾上腺素能受体刺激无法诱导气道平滑肌舒张。然而,有报道称在人心室心内膜活检中,β3-肾上腺素能受体刺激会诱导明显的负性肌力作用,这可能与Gi蛋白激活有关。本研究的目的是:(1)在HIB(内径1 - 2毫米)中确定选择性β3-肾上腺素能受体激动剂SR 59119A(N-[7-甲氧基-1,2,3,4-四氢萘-(2R)甲基]-(2R)-2-羟基-2-(3-氯苯基)乙胺盐酸盐)是否能够抑制由异丙肾上腺素、福斯高林或血管活性肠肽(VIP)诱导的腺苷酸环化酶介导的气道平滑肌舒张,以及(2)研究Gi蛋白在这种相互作用中的作用。SR 59119A(0.1微摩尔/升和1微摩尔/升)使异丙肾上腺素(分别为-0.15±0.06和-0.54±0.21对数单位,P<0.05和P<0.01)、福斯高林(-0.12±0.02和-0.30±0.05对数单位,P<0.001)以及VIP(与10^(-6)M的SR59119A作用时为-0.42±0.12对数单位,P<0.01)的浓度-反应曲线右移。SR 59119A的抑制作用:(1)通过将HIB与百日咳毒素(1微克/毫升,在21℃的克雷布斯-亨塞尔特溶液中孵育15小时)孵育而被消除,已知百日咳毒素会使Gi蛋白失活;(2)在将HIB与促炎细胞因子IL-1β(10纳克/毫升,在21℃的克雷布斯-亨塞尔特溶液中孵育15小时)孵育后增强,已知IL-1β会上调Gi蛋白表达。我们的结果表明,选择性β3-肾上腺素能受体激动剂SR59119A可能通过Gi蛋白介导的腺苷酸环化酶抑制作用来抑制人离体支气管的cAMP依赖性舒张。